Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
In regards to pharmacotherapy, patients with type 1 diabetes end up solely relying on insulin therapy for their diabetes management: what if there is an add on option?
Read More »SGLT Inhibitors as Adjunct Therapy with Insulin
New Approved Complete Diabetes Regimen in One Tablet
Diabetes has never been simpler to control with this once daily pill.
Read More »First Major Breakthrough In 20 Years For The Treatment of Diabetic Kidney Disease and Heart Failure
FDA has approved a new treatment for diabetic kidney disease, which affects one in three patients with type 2 diabetes.
Read More »New Diabetes Medications Have Reduced Heart Failure Risk by 34 Percent
Study examines SGLT-2 inhibitors versus DPP-4 in reducing cardiovascular events.
Read More »FDA Rejects Dapagliflozin for Type 1 Diabetes
The FDA rejected dapagliflozin as a treatment for type 1 diabetes although it was recently approved in Europe and Japan.
Read More »Renal Outcomes After Canagliflozin Use in Patients with Type 2 Diabetes
Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide.
Read More »CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients? ADA
Claims of improved cardiovascular outcomes from GLP-1 agonists and SGLT2 inhibitors not proven significant for black patients.
Read More »Caution for Using SGLT-2 Inhibitors in Type 1 Diabetes: ADA
There is currently a huge unmet need for non-insulin add on therapy in type 1 diabetes, but are SGLT inhibitors the right drug for the job?
Read More »EMPA-REG OUTCOME Trial: Reducing Cardiovascular Risk For T2D Patients
The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Read More »CREDENCE Trial Shows Renal and Cardiovascular Protection
Strong results motivate the ADA to update its Standard of Care for patients with diabetes.
Read More »